Posted on 06/05/2009 8:35:34 PM PDT by neverdem
SEATTLE — Optimally controlling lipid and blood pressure levels can reduce the risk of stroke by up to 65% in patients at high risk, Dr. Pierre Amarenco reported at the annual meeting of the American Academy of Neurology.
The findings are based on a new analysis of data from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. The results of this trial, as well as the findings of a recent meta-analysis of stroke-prevention trials (Lancet Neurol. 2009;8:453-63), suggest that the risk of stroke falls steadily in direct proportion to declines in the level of low-density lipoprotein cholesterol (LDL-C).
To assess how much improvements in other cardiovascular risk factors add to risk reduction, Dr. Amarenco, a neurologist at the Denis Diderot University in Paris, and his colleagues further analyzed data from SPARCL.
The researchers assessed associations between lipid and blood pressure levels at 1 month after randomization and clinical outcomes after a mean follow-up of 4.9 years.
In SPARCL, 4,732 patients at high risk for stroke because of a previous stroke or transient ischemic attack were randomized in equal numbers to treatment with atorvastatin or placebo.
The trial's main results, previously reported, showed that patients in the atorvastatin group were significantly less likely to experience both stroke and major cardiovascular events. Patients whose reductions in LDL-C level exceeded the median overall reduction (16%) in the trial population were significantly less likely to experience a stroke (hazard ratio, 0.79) or a major cardiovascular event (hazard ratio, 0.76), compared with their counterparts.
The subset analysis by Dr. Amarenco and his associates went beyond these measures. They assessed associations between lipid and blood pressure levels at 1 month after randomization and clinical outcomes after a mean follow-up of 4.9 years.
For patients whose LDL-C reductions were above the median value, their risks of events also were significantly reduced if their levels of high-density lipoprotein cholesterol (HDL-C) exceeded the median value (47 mg/dL) or if their systolic BP levels were below the median value (138 mm Hg).
There also was a trend toward additional reductions in stroke and cardiovascular events for patients whose triglyceride levels were above the median reduction (15%), as well as for those whose diastolic BP was below the median value (80 mm Hg).
A final, exploratory analysis assessed the combined effects of optimal control of four measures, based on targets outlined in national guidelines: an LDL-C level of less than 70 mg/dL, an HDL-C level of more than 50 mg/dL, a triglyceride level of less than 150 mg/dL, and a BP of less than 120/80 mm Hg.
Optimal control was achieved for one measure by 24%, for two measures by 41%, for three by 19%, and for four by 2%.
“There was a dose-response relationship,” Dr. Amarenco observed. The hazard ratios for both stroke and major cardiovascular events decreased significantly as the number of optimally controlled measures increased.
Compared with trial participants who did not achieve optimal control of any measures, patients achieving optimal control of all four measures had a 65% relative reduction in the risk of stroke and a 75% relative reduction in the risk of major cardiovascular events.
Dr. Amarenco reported that he has received honoraria from Pfizer Inc. as a member of the steering committee and speaker fees. The SPARCL trial was sponsored by Pfizer Inc.
If socialized healthcare is inacted, I can see manditory edicts to prescribe BP/Statins to all citizens above age 35
Funny how these studies never talk about all the other side effects of the statins that can kill you.
bookmark
Thanks for the ping.
The program is working fine for me
Don't you just love it - another objective study from a big pharm sock puppet. Funny how the good doctor never mentioned how statins trash CQ-10 - yeah - that little foundational enzyme essential for proper heart and neurological function, inter alia. A doctor friend of mine who does research at NIH says that Pfizer plans to come out with a new pill called Lipitor Plus - which will consist of the same old Lipitor with a dose of CQ-10 included. Cute, really cute. Not to mention the fact that many many people can get their LDLs down with diet, exercise, and alternatives to statins. Of course trashing CQ-10 is just one of the more spectacular side effects of Lipitor - the actual list is sufficient to cause any sentient, prospective victim to take a rain check. Luckily for Pfizer and the rest there are droves of sheeple who would rather take a pill that plays dice with their liver and who knows what else.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.